provision of informed consent prior to any study specific procedures

diagnosis of t2dm

current antihyperglycaemic treatment with metformin immediate release formulation monotherapy >/= 1500 mg/day at a stable dose for at least 10 weeks prior to enrolment. other treatment with oads within the 10 weeks prior to enrolment is not permitted.

hba1c ≥ 6.7% and ≤10.5%, based on central laboratory values from screening visit, and enrolment visit 1.

diagnosis of type 1 diabetes mellitus, known diagnosis of maturity onset diabetes of the young (mody) or secondary causes of diabetes mellitus

history of diabetic ketoacidosis

symptoms of poorly controlled diabetes including, but not limited to, marked polyuria, polydipsia, and/or greater than 10% weight loss during the 3 months prior to enrolment

fpg >270 mg/dl (>15.0 mmol/l)

bmi >45 kg/m2